Skip to main content
. 2022 Apr 25;12:857590. doi: 10.3389/fonc.2022.857590

Figure 2.

Figure 2

Selective ERβ agonists demonstrate significant cytotoxicity in ERα+ parental and respective endocrine-resistant breast cancer cell lines. Cytotoxicity assays were performed on immortalized MCF10A, ER-positive MCF7 and T47D, endocrine-resistant MCF7 and T47D, CDK4/6 inhibitor-resistant MCF7 and T47D, and CDK6 overexpressing MCF7 (MCF7-CDK6 O/E) cells. Viable cells were measured after 7 days of treatment with DMSO (control) or the drugs at the indicated concentrations using CellTiterGlo assay. The percentage of viable cells is shown relative to DMSO vehicle-treated controls (mean ± SD, *p < 0.05, **p < 0.01). Assays were performed in quadruplicates (three experimental replicates). Cell viability assay performed after treatment with (A, C) OSU-ERb-12 and (B, D) LY500307. TamR, tamoxifen resistant; FasR, fulvestrant resistant; CDK6 O/E, CDK6 overexpressing; CDK4/6iR, CDK4/6 inhibitor resistant; MPP, methyl-piperidino-pyrazole.